AustralianSuper Pty Ltd Acquires New Stake in Cencora, Inc. $COR

AustralianSuper Pty Ltd acquired a new stake in Cencora, Inc. (NYSE:COR) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 83,804 shares of the company’s stock, valued at approximately $26,191,000.

A number of other large investors have also modified their holdings of the business. Elo Mutual Pension Insurance Co lifted its stake in shares of Cencora by 28.1% in the third quarter. Elo Mutual Pension Insurance Co now owns 29,808 shares of the company’s stock worth $9,316,000 after buying an additional 6,535 shares in the last quarter. Fisher Asset Management LLC raised its holdings in Cencora by 47.2% in the 3rd quarter. Fisher Asset Management LLC now owns 1,359 shares of the company’s stock valued at $425,000 after acquiring an additional 436 shares during the last quarter. Fairtree Asset Management Pty Ltd lifted its stake in Cencora by 84.8% in the 3rd quarter. Fairtree Asset Management Pty Ltd now owns 4,266 shares of the company’s stock worth $1,333,000 after purchasing an additional 1,957 shares in the last quarter. River Wealth Advisors LLC boosted its holdings in shares of Cencora by 6.4% during the 3rd quarter. River Wealth Advisors LLC now owns 42,905 shares of the company’s stock worth $13,409,000 after purchasing an additional 2,573 shares during the last quarter. Finally, Arete Wealth Advisors LLC grew its position in shares of Cencora by 3.5% in the third quarter. Arete Wealth Advisors LLC now owns 2,280 shares of the company’s stock valued at $719,000 after purchasing an additional 78 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Stock Down 0.3%

Cencora stock opened at $371.48 on Wednesday. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. The firm has a 50 day moving average price of $353.00 and a 200 day moving average price of $335.29. Cencora, Inc. has a fifty-two week low of $248.59 and a fifty-two week high of $377.54. The company has a market capitalization of $72.26 billion, a PE ratio of 44.65, a price-to-earnings-growth ratio of 1.74 and a beta of 0.68.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm had revenue of $85.93 billion for the quarter, compared to the consensus estimate of $86.12 billion. During the same quarter in the previous year, the business earned $3.73 EPS. The company’s quarterly revenue was up 5.5% compared to the same quarter last year. Research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were paid a $0.60 dividend. The ex-dividend date of this dividend was Friday, February 13th. This represents a $2.40 annualized dividend and a dividend yield of 0.6%. Cencora’s dividend payout ratio (DPR) is presently 28.85%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on COR shares. Robert W. Baird set a $415.00 price objective on Cencora in a research report on Tuesday, January 13th. Bank of America cut their target price on Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a research note on Monday, January 5th. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Mizuho upped their price objective on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Finally, UBS Group lifted their target price on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Cencora has an average rating of “Moderate Buy” and a consensus target price of $399.00.

Insider Activity at Cencora

In other news, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the sale, the executive vice president directly owned 18,796 shares in the company, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the transaction, the executive vice president directly owned 23,891 shares of the company’s stock, valued at $8,173,111.10. The trade was a 12.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 15,220 shares of company stock worth $5,282,867. Corporate insiders own 0.38% of the company’s stock.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.